Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (ALNY:NASDAQ)
· seekingalpha.com
Alnylam (ALNY) updates: Amvuttra HELIOS-B analyses support ATTR-CM use incl. tafamidis patients; zilebesiran shows BP promise.
Alnylam Pharmaceuticals (ALNY) on Sunday presented new analyses supporting the use of Amvuttra across a range of patients with transthyretin amyloidosis, includ...